TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQX:ATBPF) announces that it has completed the acquisition of the remainder 15% minority interest in Citagenix Inc. (“Citagenix”), a Montreal-based sales and distribution company with a focus on regenerative medicine. The Citagenix acquisition was previously announced in Antibe’s news releases of October 6, 2015 and October 16, 2015.
